| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | 10-Q |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | DEFA14A |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
LONDON, Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided ... |
| 05 Nov 2026 | SCHEDULE 13G |
| 19 Oct 2026 | DEFA14A |
| 19 Oct 2026 | DEFA14A |
| 19 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
THIS TRANSACTION AGREEMENT (this “Agreement”), dated as of October 18, 2026, is by and between MERCK KGAA, DARMSTADT, GERMANY, a German corporation with general partners (“Purchaser”), and SILENCE THERAPEUTICS PLC, a public limited compa... |
| 13 Oct 2026 | SCHEDULE 13G/A |
| 13 Oct 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13D/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 |
Form 4: Griffiths Richard Ian, 10% owner
Acquired 5,484,320 American Depositary Shares (Open Market Sale) |
| 12 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
12,962,963 AMERICAN DEPOSITARY SHARES OF THE COMPANY, EACH REPRESENTING THREE ORDINARY SHARES, NOMINAL VALUE £0.05 PER SHARE |
| 12 Aug 2026 | 424B5 |
| 11 Aug 2026 | S-3MEF |
| 10 Aug 2026 | 424B5 |
| 10 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO |
| 10 Aug 2026 | 10-Q |
Loading...